Top Markets
#1 Black Phoenix Black Phoenix +167.48%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +43.60%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.51%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#8 Test Test +17.66%
#9 Victoria VR Victoria VR +12.65%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +10.37%
Coin of the day
Black Phoenix Black Phoenix
Настройки
Язык
Pусский
Валюта
USD
Тема
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Ранг среди акций #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Цена акции
$0.0005
Последняя синхронизация: 2026-08-11
Рыночная капитализация
$10.28K
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля VIA Pharmaceuticals, Inc. (VIAP)

Категория

Healthcare
Выручка компании VIA Pharmaceuticals, Inc. (VIAP)
Выручка на Aug 2026 TTM: 0
Согласно последним финансовым отчетам VIA Pharmaceuticals, Inc., текущая выручка компании (TTM) составляет 0. В 2026 году компания получила выручку 0 равна выручке в 2026 году, которая составила 0. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки VIA Pharmaceuticals, Inc. с 2026 по 2026
Выручка на конец каждого года
Год Выручка Изменить
Недостаточно данных для указанных дат.
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US